Literature DB >> 11703496

A decision aid for men with early stage prostate cancer: theoretical basis and a test by surrogate patients.

D Feldman-Stewart1, M D Brundage, L Van Manen.   

Abstract

BACKGROUND: We developed a decision aid for patients with curable prostate cancer based on Svenson's DiffCon Theory of Decision Making. This study was designed to determine if surrogate patients using the aid could understand the information presented, complete all tasks, show evidence of differentiation, and arrive at a preferred treatment choice.
METHODS: Men, at least 50 years old and never diagnosed with prostate cancer, were recruited through local advertisements. Participants were asked to imagine that they were a case-scenario patient. Then they completed the decision aid interview, which included three components: (i) information presentation, with comprehension questions, (ii) exercises to help identify attributes important to the decision, and (iii) value-clarification exercises.
RESULTS: Sixty-nine men volunteered. They had a mean age of 61.2 (range 50-83) years, 37% had no formal education beyond high school, and 87% were living with a partner. All participants completed all aspects of the interview. They answered an average of 10 comprehension questions each, with a mean of 94.7% correct without a prompt. Each attribute in the information presented was identified by at least one participant as important to his decision. Participants identified a median of five attributes as important (ranges 1-14) at each of three points during the interview; 75% changed at least one important attribute during the interview. Forty-nine per cent of participants also identified attributes as important that were not included in the presented information. Participants showed a wide range of values in each of seven trade-off exercises. Eighty-eight per cent of participants showed evidence of differentiation; 75% had a clear treatment preference by the end of the interview.
CONCLUSIONS: Our decision aid appears to meet its goals for surrogate patients and illustrates the strengths of the DiffCon theory. The ability of the aid to accommodate wide variability, both in information needs and in important attributes, is a particular strength of the decision aid. It now requires testing in patients with prostate cancer.

Entities:  

Mesh:

Year:  2001        PMID: 11703496      PMCID: PMC5060079          DOI: 10.1046/j.1369-6513.2001.00139.x

Source DB:  PubMed          Journal:  Health Expect        ISSN: 1369-6513            Impact factor:   3.377


  13 in total

Review 1.  Decision aids for patients considering options affecting cancer outcomes: evidence of efficacy and policy implications.

Authors:  A M O'Connor; V Fiset; C DeGrasse; I D Graham; W Evans; D Stacey; A Laupacis; P Tugwell
Journal:  J Natl Cancer Inst Monogr       Date:  1999

Review 2.  Feasibility and effects of decision aids.

Authors:  S Molenaar; M A Sprangers; F C Postma-Schuit; E J Rutgers; J Noorlander; J Hendriks; H C de Haes
Journal:  Med Decis Making       Date:  2000 Jan-Mar       Impact factor: 2.583

3.  What questions do patients with curable prostate cancer want answered?

Authors:  D Feldman-Stewart; M D Brundage; C Hayter; P Groome; J C Nickel; H Downes; W J Mackillop
Journal:  Med Decis Making       Date:  2000 Jan-Mar       Impact factor: 2.583

4.  The Control Preferences Scale.

Authors:  L F Degner; J A Sloan; P Venkatesh
Journal:  Can J Nurs Res       Date:  1997

5.  The information required by patients with early-stage prostate cancer in choosing their treatment.

Authors:  D Feldman-Stewart; M D Brundage; J C Nickel; W J MacKillop
Journal:  BJU Int       Date:  2001-02       Impact factor: 5.588

6.  Towards a perspective theory of decision making and judgment.

Authors:  H Montgomery
Journal:  Acta Psychol (Amst)       Date:  1994-11

7.  Validation of a decisional conflict scale.

Authors:  A M O'Connor
Journal:  Med Decis Making       Date:  1995 Jan-Mar       Impact factor: 2.583

8.  Patients' willingness to enter clinical trials: measuring the association with perceived benefit and preference for decision participation.

Authors:  H A Llewellyn-Thomas; M J McGreal; E C Thiel; S Fine; C Erlichman
Journal:  Soc Sci Med       Date:  1991       Impact factor: 4.634

9.  Narrowing the options: the process of deciding on prostate cancer treatment.

Authors:  M E O'Rourke
Journal:  Cancer Invest       Date:  1999       Impact factor: 2.176

10.  Using a treatment-tradeoff method to elicit preferences for the treatment of locally advanced non-small-cell lung cancer.

Authors:  M D Brundage; J R Davidson; W J Mackillop; D Feldman-Stewart; P Groome
Journal:  Med Decis Making       Date:  1998 Jul-Sep       Impact factor: 2.583

View more
  10 in total

1.  The Personal Patient Profile-Prostate decision support for men with localized prostate cancer: a multi-center randomized trial.

Authors:  Donna L Berry; Barbara Halpenny; Fangxin Hong; Seth Wolpin; William B Lober; Kenneth J Russell; William J Ellis; Usha Govindarajulu; Jaclyn Bosco; B Joyce Davison; Gerald Bennett; Martha K Terris; Andrea Barsevick; Daniel W Lin; Claire C Yang; Greg Swanson
Journal:  Urol Oncol       Date:  2011-12-07       Impact factor: 3.498

2.  The Genomics ADvISER: development and usability testing of a decision aid for the selection of incidental sequencing results.

Authors:  Yvonne Bombard; Marc Clausen; Chloe Mighton; Lindsay Carlsson; Selina Casalino; Emily Glogowski; Kasmintan Schrader; Michael Evans; Adena Scheer; Nancy Baxter; Jada G Hamilton; Jordan Lerner-Ellis; Kenneth Offit; Mark Robson; Andreas Laupacis
Journal:  Eur J Hum Genet       Date:  2018-04-27       Impact factor: 4.246

Review 3.  A systematic review of information in decision aids.

Authors:  Deb Feldman-Stewart; Sarah Brennenstuhl; Kathryn McIssac; Joan Austoker; Agathe Charvet; Paul Hewitson; Karen R Sepucha; Tim Whelan
Journal:  Health Expect       Date:  2007-03       Impact factor: 3.377

4.  Patient-focussed decision-making in early-stage prostate cancer: insights from a cognitively based decision aid.

Authors:  Deb Feldman-Stewart; Michael D Brundage; Lori Van Manen; Ola Svenson
Journal:  Health Expect       Date:  2004-06       Impact factor: 3.377

5.  Preference assessment of recruitment into a randomized trial for adolescent idiopathic scoliosis.

Authors:  Lori A Dolan; Vani Sabesan; Stuart L Weinstein; Kevin F Spratt
Journal:  J Bone Joint Surg Am       Date:  2008-12       Impact factor: 5.284

6.  Overall information needs of early-stage prostate cancer patients over a decade: highly variable and remarkably stable.

Authors:  Deb Feldman-Stewart; Sarah Brennenstuhl; Michael D Brundage; D Robert Siemens
Journal:  Support Care Cancer       Date:  2008-10-02       Impact factor: 3.603

7.  Development and evaluation of the personal patient profile-prostate (P3P), a Web-based decision support system for men newly diagnosed with localized prostate cancer.

Authors:  Donna L Berry; Barbara Halpenny; Seth Wolpin; B Joyce Davison; William J Ellis; William B Lober; Justin McReynolds; Jennifer Wulff
Journal:  J Med Internet Res       Date:  2010-12-17       Impact factor: 5.428

8.  A global, incremental development method for a web-based prostate cancer treatment decision aid and usability testing in a Dutch clinical setting.

Authors:  Maarten Cuypers; Romy Ed Lamers; Paul Jm Kil; Regina The; Klemens Karssen; Lonneke V van de Poll-Franse; Marieke de Vries
Journal:  Health Informatics J       Date:  2017-07-27       Impact factor: 2.681

9.  Toward a model for field-testing patient decision-support technologies: a qualitative field-testing study.

Authors:  Rhodri Evans; Glyn Elwyn; Adrian Edwards; Eila Watson; Joan Austoker; Richard Grol
Journal:  J Med Internet Res       Date:  2007-07-13       Impact factor: 5.428

10.  Values clarification in a decision aid about fertility preservation: does it add to information provision?

Authors:  Mirjam M Garvelink; Moniek M ter Kuile; Anne M Stiggelbout; Marieke de Vries
Journal:  BMC Med Inform Decis Mak       Date:  2014-08-09       Impact factor: 2.796

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.